TEMENOS
13.4.2021 09:02:09 CEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that BlueShore Financial, a boutique full service financial institution, is digitally transforming with Temenos. Powered by Temenos Infinity, the market-leading omnichannel digital banking product, BlueShore will extend its ‘HighTech-HighTouch’ experience to clients by leveraging explainable artificial intelligence (XAI). BlueShore will replicate the in-branch experience of its Financial Spa™ Branch designed around client-centered amenities, personalized service and expert advice, across all channels and devices, from onboarding to servicing through to retention.
BlueShore clients are largely technologically and financially literate, but are time-starved and have complex financial needs. As such, BlueShore is focused on delivering expert advice and a premium, personalized client experience, both in-person and virtually, via the channel of their clients’ choice. In November 2020, as part of its initiative to build human connections in the digital era, and deliver a technology experience that fits its clients’ lifestyle, BlueShore signed a contract for Temenos Infinity Engage , a state-of-the-art mobile messaging app that connects BlueShore Solution Centre and Financial Advisors with clients. The expansion of the relationship to include the full Temenos Infinity digital platform, Temenos Data Lake , Temenos Explainable AI (XAI) and Temenos Payments will take this further, as BlueShore executes a data-driven, cutting-edge digital strategy.
BlueShore has been a long-standing Temenos partner, using Temenos Transact to create a high-performing cost-efficient core banking environment. Leveraging Temenos Analytics, embedded into the core banking platform, BlueShore created what it calls ‘bluegorithms’, proprietary algorithms that measure qualities such as engagement score, digital usage and price sensitivity. With the new end-to-end, fully integrated digital ecosystem, BlueShore will benefit from:
- Reduced complexity.
- An enhanced 360-degree customer view.
- The ability to leverage both blended client data from standard structured data (such as form entries) to unstructured data (such as social media and voice).
- Real-time analytics to gain valuable insights into customer behavior and preferences, fed into Temenos XAI to automatically deliver hyper-personalized experiences with tailored recommendations and contextualized advice.
- An API-first, open platform that can enrich BlueShore’s data with third-party sources, proactively facilitating open banking ahead of new regulations emerging in Canada. BlueShore will have access to over 100 of the latest Open Banking APIs being deployed globally.
- Next-generation payments technology that supports ISO20022 standards and real-time payments, enabling BlueShore to take further advantage of Canadian Payments Modernization.
Chris Catliff, President and CEO, BlueShore Financial, said: “We are delighted to start this exciting next phase of our digital transformation journey with Temenos. For over a decade, Temenos has been a strong partner of ours in our commitment to improving our clients’ financial well-being. With this expansion of the relationship, we will be able to take the Financial Spa™ experience that BlueShore is known for in-person – encouraging engaging conversations and genuine value – and deliver that in the digital realm. With Temenos, we can pursue new and untapped market opportunities with differentiated products and services that will put us at the forefront of Open Banking and Payments Modernization opportunities. We look forward to continuing to innovate with Temenos.”
Jacqueline White, President, Americas, Temenos, said: “Financial institutions recognize the value of their data as they seek to personalize customer engagement, but they don’t necessarily understand how to leverage it. BlueShore has been a pioneer for many years in leveraging data to take a highly targeted, personalized approach and deliver a premium experience. With the end-to-end Temenos platform, encompassing modernized payments and explainable AI, BlueShore will create differentiated experiences for its clients, empowering them with tailored recommendations and contextualized advice.”
– Ends –
About BlueShore Financial
BlueShore Financial is a boutique financial institution providing a full range of personal and business banking, wealth management, insurance and commercial lending solutions. With a branch network located across the Lower Mainland and Sea-to-Sky Corridor, BlueShore Financial helps clients achieve financial wellness® through personalized solutions and expert advice, delivered in a unique Financial Spa® branch environment. BlueShore Financial manages over $6.5 billion in Assets Under Administration and is consistently ranked among the top 20 financial planning firms in Metro Vancouver.
BlueShore Financial is an Imagine Canada Caring Company, contributing at least 1% of pre-tax profits annually to charities and not-for-profit organizations within the communities it serves. BlueShore Financial is the operating name of BlueShore Financial Credit Union.
Follow and connect with us on Facebook , Instagram , LinkedIn or Twitter .
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005104/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom